ORIC Pharmaceuticals Presents Preclinical Data for Rinzimetostat at ESMO Congress 2026

At the ESMO Congress 2026, ORIC Pharmaceuticals presented preclinical data for rinzimetostat, a prostate cancer treatment candidate. The findings indicate that targeting PRC2 via EED may provide benefits over EZH2 targeting, potentially limiting tumor adaptation and improving sensitivity to androgen receptor inhibition. These results support the ongoing Himalayas-1 Phase 3 trial of rinzimetostat across the prostate cancer spectrum and reinforce the rationale for combining PRC2 inhibition with AR-targeted therapies.